PF-Atlas › Clinical Trials › NCT00189176

Safety Study of Tetrathiomolybdate in Patients With Idiopathic Pulmonary Fibrosis

Tetrathiomolybdate · Phase 1

Registry ID
NCT00189176
Phase
Phase 1
Status
Completed
Drug / intervention
Tetrathiomolybdate
Sponsor
University of Michigan
Start
2003-03
Enrollment
23
Locations
1

About this trial

This study will evaluate the safety of the administration of a copper chelating agent, tetrathiomolybdate, for patients with idiopathic pulmonary fibrosis that have failed previous treatment. The primary endpoint for this study is safety with secondary endpoints including change in pulmonary function, exercise capacity, and quality of life.

View NCT00189176 on ClinicalTrials.gov →

Explore related

All Tetrathiomolybdate trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT00189176 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.